secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001759425-25-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q2 revenue $127.8M; raises FY 2025 guidance to $490-510M
--------------------------------------------------------------

- Q2 global net product sales $127.8M, up 64% YoY from $77.9M.
- LIVMARLI sales $88.2M (+87% YoY); Bile Acid Medicines $39.6M (+30%).
- FY 2025 revenue guidance raised to $490-510M from prior range.
- Cash $321.7M; volixibat VISTAS topline expected Q2 2026.
- MRM-3379 Phase 2 in Fragile X expected Q4 2025 initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/0001759425-25-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/mirm-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001759425-25-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer